Clinical Trial Update: TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial in China evaluating TGRX-326 for advanced non-small cell lung cancer is currently active but not recruiting. Sponsored by Shenzhen Target…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TGRX-326

Snippet

Sponsor: Shenzhen TargetRx Co., Ltd. | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING